Meeting
2014 ASCO Annual Meeting
Interrelationship of primary and secondary mutations in gastrointestinal stromal tumors during TKI therapy.
Authors
Peter Hohenberger
University Medical Center Mannheim, Department of Surgery, Mannheim, Germany
Peter Hohenberger , Ming Wang , Carina Heydt , Alexander Marx , Ulrich Ronellenfitsch , Eva Wardelmann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Gastrointestinal Stromal Tumors (GIST)
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 10518)
DOI
10.1200/jco.2014.32.15_suppl.10518
Abstract #
10518
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.
First Author: Steven Bialick
Poster
2013 ASCO Annual Meeting
Use of ponatinib to inhibit kinase mutations associated with drug-resistant gastrointestinal stromal tumors (GIST).
First Author: Michael C. Heinrich
Poster
2011 ASCO Annual Meeting
A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study.
First Author: M. Ryu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Exploration of drug resistance in advanced gastrointestinal stromal tumor.
First Author: Hao Xu